|
|
|
18.09.25 - 15:54
|
Dead Cat Bounce Or Bottom? Novo Jumps On Ozempic Study As Goldman Weighs In (ZeroHedge)
|
|
|
Dead Cat Bounce Or Bottom? Novo Jumps On Ozempic Study As Goldman Weighs In
Novo Nordisk shares jumped the most in 18 months in Copenhagen trading on Thursday after its diabetes wonder drug Ozempic beat Eli Lilly's older drug Trulicity in a real-world survey of 60,000 Medicare patients with diabetes and heart disease.
The new study was revealed at the European Association for the Study of Diabetes conference in Vienna earlier today. It showed that Medicare patients who took Ozempic were 23% less likely to suffer heart attacks, strokes, or death compared with those on Trulicity.
Shares of Novo Nordisk in Copenhagen surged 7% on the announcement of the study, but remain down 36.5% year-to-date and more than 61.5% below the June 2024 peak of DKK 1,000. For Goldman analysts like Novo superbull James Quigley, the question is whether the 37% rebound since early August marks an actual bottom, or just another dead cat bounce.
Quigley penned a note to clients about the key takeaways from the...
|
|
|
18.09.25 - 14:03
|
GeneDx Appoints Visionary AI and Precision Medicine Leader Dr. Thomas Fuchs to Board of Directors (Business Wire)
|
|
|
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced the appointment of Thomas Fuchs, Dr.sc., Chief AI Officer at Eli Lilly and Company, to its board of directors.
“With the world's largest rare disease data set, we're only beginning to realize AI's full potential to deliver faster, more precise insights to clinicians and families, accelerating answers for those who need them most,” said Katherine Stueland, President and CEO of GeneDx. “Dr. Fuchs' experience scaling AI and machine learning infrastructure and algorithms for practical, high-impact applications in diagnostic medicine is invaluable. We both share the goal of unlocking new ways to improve patient outcomes and accelerate drug discovery and development.”
As the SVP and Chief AI Officer at Lilly, Dr. Fuchs provides vision, strategic direction, and overall leadership of AI initiatives for drug discovery, clinical trials, manufacturing, commer...
|
|
|
|
|
18.09.25 - 12:36
|
Novo Nordisk shares shoot up amid promising results for anti-obesity pill (The Guardian)
|
|
|
Stock climbs above £6.5bn in early trading as trial shows 'significant weight loss' for pill version of WegovyBusiness live – latest updatesThe value of the drugmaker Novo Nordisk has shot up by more than £6.5bn after research showed its new anti-obesity pill resulted in almost as much weight loss as its Wegovy jab, as it races against its US rival Eli Lilly to get a tablet treatment to market.Stock in the Danish company climbed by more than 4.5% on Thursday morning on hopes it could claw back market share lost to Eli Lilly and cheaper generic versions of GLP-1 drugs. Shares have fallen nearly 60% in the past year as sales slowed. Continue reading......
|
|
|
|
|
18.09.25 - 10:54
|
Novo Nordisk findet ein gesundes Maß (MarktEinblicke)
|
|
|
Sowohl Novo Nordisk als auch Eli Lilly versuchen die Chancen im Bereich GLP1-Mittel zu nutzen, die Dänen scheinen derzeit die günstigere Alternativen zu sein.
The post Novo Nordisk findet ein gesundes Maß first appeared on marktEINBLICKE....
|
|
|
|
|
|
|
|
|
|
|
|
|
17.09.25 - 16:42
|
Lilly′s GLP-1 Pill Outperforms Older Novo Drug (Bloomberg)
|
|
|
Patients on Eli Lilly & Co.'s experimental diabetes pill lost more weight and had better blood sugar control than those on an older, approved rival from Novo Nordisk in the first head-to-head trial of the two medicines. Madison Muller reports on “Bloomberg Open Interest.”...
|
|
|
|
|
17.09.25 - 15:31
|
Eli Lilly Aktie: Vom Überflieger zur Verschnaufpause? (Aktiencheck)
|
|
|
Hamburg (www.aktiencheck.de) - Eli Lilly-Aktienanalyse der Berenberg:
Berenberg habe die Aktie von Eli Lilly and Company (ISIN: US5324571083, WKN: 858560, Ticker-Symbol: LLY, NYSE-Symbol: LLY) von "buy" auf "hold" abgestuft und das Kursziel von 970 von 830 USD gesenkt. Die Privatbank erwarte, dass Eli Lilly im Adipositas-Segment am Steuer bleibe, glaube jedoch, dass der Aufwertungszyklus des Adipositas-Marktes seinen Höhepunkt erreicht habe. [mehr]...
|
|
|
|
|
|
|
|
|
|
|
17.09.25 - 12:36
|
Novo Nordisk: Neuer Favorit – Aktie nimmt Kurs auf wichtige Hürde (Der Aktionaer)
|
|
|
Die Aktie von Novo Nordisk zeigt sich derzeit stark. Auch zur Wochenmitte kann das Papier deutlich zulegen. Unterstützung erhält die Aktie von guten Studiendaten sowie einem positiven Analystenkommentar. Die Privatbank Berenberg spricht für Novo Nordisk nun eine Kaufempfehlung aus, während sie die Aktie des Konkurrenten Eli Lilly auf „Hold“ abgestuft hat....
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
